News und Analysen

Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock

Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock

Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine

Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine

Shares of Knight-Swift Transportation (NYSE: KNX) were moving higher today after the diversified transportation company topped analyst estimates in its third-quarter earnings report.

As of 11:27

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --

For a company in the midst of a transition away from the medicine that made it a star performer over the last decade, AbbVie's (NYSE: ABBV) valuation looks surprisingly high. Why is the market

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been in agreement on a lot since the beginning of the pandemic. They both recognized the importance of eventually launching combined vaccines --

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been in agreement on a lot since the beginning of the pandemic. They both recognized the importance of eventually launching combined vaccines --

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q3 2023 Earnings CallOct 18, 2023, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press

Diabetes care and aesthetics. Those are two areas of healthcare that should provide investors with ample growth opportunities in the long run. Two companies that are in solid positions to capitalize

Diabetes care and aesthetics. Those are two areas of healthcare that should provide investors with ample growth opportunities in the long run. Two companies that are in solid positions to capitalize

Exelixis (NASDAQ: EXEL) is not exactly a household name in the biotech industry, but that hasn't stopped the company from crushing the market this year -- rising over 30%. Perhaps one key reason

Stocks that are crashing in value can sometimes make for good contrarian investments -- provided that there's a reason to expect a turnaround. But in some situations, investors are better off just

Stocks that are crashing in value can sometimes make for good contrarian investments -- provided that there's a reason to expect a turnaround. But in some situations, investors are better off just

Stocks that are crashing in value can sometimes make for good contrarian investments -- provided that there's a reason to expect a turnaround. But in some situations, investors are better off just

Cathie Wood isn't known for being a value investor. However, the Ark Invest CEO won't pass up the opportunity to scoop up shares of innovative companies when they're available at a lower price.

Pharmaceutical giant Pfizer (NYSE: PFE) wasn't looking very tall or strong on the stock exchange Tuesday. The company's share price dipped by nearly 2% over the course of the trading session

Pharmaceutical giant Pfizer (NYSE: PFE) wasn't looking very tall or strong on the stock exchange Tuesday. The company's share price dipped by nearly 2% over the course of the trading session

Industries with endless demand are great places to find dividend stocks. Healthcare might be the best example of this. No matter how much technology changes, the need to prevent and treat disease